Annette Fasan

Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia

Chiara Elena, Anna Gallì, Esperanza Such et al. · Blood · 2016 · 344 citations · Full text

EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation

Günther Richter, Stephanie Plehm, Annette Fasan et al. · Proceedings of the National Academy of Sciences · 2009 · 304 citations · Full text

Histone Modifications, Epigenetic Change, Ezh2 Knock +18

Landscape of TET2 mutations in acute myeloid leukemia

Tamara Alpermann, Vera Grossmann, Andreas Kowarsch et al. · Leukemia · 2011 · 257 citations

Hematological Malignancy, Mixed-phenotype Acute Leukemia, Acute Myeloid Leukemia +5

The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases

Anna Stengel, Wolfgang Kern, Torsten Haferlach et al. · Leukemia · 2016 · 224 citations

Genome Instability, Medicine, Survival Varies +10

ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome

Susanne Schnittger, Christiane Eder, Sabine Jeromin et al. · Leukemia · 2012 · 208 citations

Intermediate Risk Karyotype, Adverse Outcome, Genetic Disorder +6